Characterization of on-target adverse events caused by TRK inhibitor therapy von Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A.

Volltext

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma von Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

Volltext

130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumor... von Garmezy, B., Borad, M., Lin, C-C., Chen, L-T., Perez, C.A., Kato, S., Tam, B., Severson, P., Quah, C.S., Harding, J.J.

Volltext

371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers von Harding, J.J., Hofheinz, R.D., Elez Fernandez, M.E., Kuboki, Y., Rasco, D., Cecchini, M., Shen, L., Archuadze, S., Geng, J., Haderk, F., Pant, S.

Volltext

101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study von Wasan, H.S., Harding, J.J., Fan, J., Oh, D-Y., Choi, H.J., Kim, J.W., Chang, H-M., Bao, L., Sun, H., Macarulla, T., Xie, F., Metges, J-P., Ying, J., Bridgewater, J.A., Tejani, M., Chen, E.Y., Ducreux, M.P., Ma, J., Garfin, P., Pant, S.

Volltext

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers von Wu, J., Liu, D., Offin, M., Lezcano, C., Torrisi, J. M., Brownstein, S., Hyman, D. M., Gounder, M. M., Abida, W., Drilon, A., Harding, J. J., Sullivan, R. J., Janku, F., Welsch, D., Varterasian, M., Groover, A., Li, B. T., Lacouture, M. E.

Volltext

745P - Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients von Awada, A.H., Harding, J.J., Kotecki, N., Aftimos, P.G., Decaens, T., Dreyer, C., Ansaldi, C., Rachid, M., Serdjebi, C., Halfon, P., Abou-Alfa, G.K., Raymond, E.

Volltext

Dr. Antoinette Pirie (1905–1991) von Harding, J.J.

Volltext

LBA38_PR - CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellu... von Yau, T., Park, J.W., Finn, R.S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J.J., Merle, P., Rosmorduc, O., Wyrwicz, L., Schott, E., Choo, S.P., Kelley, R.K., Begic, D., Chen, G., Neely, J., Anderson, J., Sangro, B.

Volltext

Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats von Yan, Hong, Guo, Yong, Zhang, Jie, Ding, Zhenghua, Ha, Wenjing, Harding, J J

Volltext

The Ageing Lens von Bron, A.J., Vrensen, G.F.J.M., Koretz, J., Maraini, G., Harding, J.J.

Volltext

Supplementary Material for: Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Patients with Fibrolamellar Carcinoma von G.K., Abou-Alfa, T., Meyer, R.K.G., Do, S.A., Piha-Paul, J.S., Light, S., Sherrin, A., Yaqubie, A.C., O’Neill, J.J., Harding, R., Al-Rajabi, C.S., Denlinger, P., Cano, A.S., Cornelius, E.M., O'Reilly, D., DiPrimeo, L.D., Eli, J.D., Gordan, D.B., Solit

Volltext bestellen

The Effect of Modification of α-Crystallin by Prednisolone-21-Hemisuccinate and Fructose 6-Phosphate on Chaperone Activity von Hook, D.W.A., Harding, J.J.

Volltext

Supplementary Material for: First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers von J.J., Harding, A., Awada, G., Roth, T., Decaens, P., Merle, N., Kotecki, C., Dreyer, C., Ansaldi, M., Rachid, S., Mezouar, A., Menut, E.N., Bestion, V., Paradis, P., Halfon, G.K., Abou-Alfa, E., Raymond

Volltext bestellen

The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione von Ajiboye, R., Harding, J.J.

Volltext

Cushioning conversion machine, cushion conversion network and relative using method von J.J. HARDING, A. HOFFMANN

Volltext bestellen

Collagen crosslinking: isolation of two crosslinked peptides involving alpha-CB(3-5) from bovine scleral collagen von Crabbe, M.J.C, Harding, J.J

Volltext

ASPIRIN-LIKE ANALGESICS AND CATARACT von Harding, J.J., Van Heyningen, R.

Volltext

Collagen crosslinking: isolation of a dimeric crosslinked peptide of alpha1-CB6 from bovine corneal and scleral collagens von Harding J.J, Crabbe, M.J.C

Volltext

The nature and origin of the urea-insoluble protein of human lens von Harding, J.J.

Volltext